SELF-TESTING MARKET ANALYSIS

Self-Testing Market, by Product Type (Kits (Self-testing kits, Self-collection kits) Self-testing Devices), by Application Type (Blood Glucose Testing, Pregnancy Testing, Pulmonary Function Testing, Urinary Tract Infection Testing, Sexually transmitted infections (STIs) Testing, Genetic Testing, Vitamin and Mineral Deficiency Testing, COVID Testing, Allergy Testing, Gastrointestinal Screening, Hormone Testing, Food Sensitivity Testing, Others (Infectious Disease Testing, etc.)), by Sample Type (Blood, Saliva, Nasal, Stool, Urine and Others (Vaginal Swab Sample and Breathe Sample)), by Test Type (Laboratory Tests, Point of Care Tests/Homecare Tests), by Distribution Channel (Offline (Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Supermarkets and Hypermarket) and Online), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America)- Size, Share, Outlook, and Opportunity Analysis, 2024 - 2031

Published In : Mar 2024
Code : CMI4902
Pages :197
Formats :
Excel and PDF
Industry : Clinical Diagnostic

Market News

Recent Developments

In October 2023, PHASE Scientific Americas, a rapidly developing global biomedical company, announced the launch of INDICAID health, a new line of at-home health tests and digital health experiences. INDICAID health provides patients with the convenience of testing from their own homes, ensuring that they receive personalized care that aligns with their unique needs and lifestyle.

In March 2023, Lucira Health, Inc., a medical technology company, announced the nationwide launch of its breakthrough Lucira COVID-19 & Flu Home Test in the U.S., as well as the combination test's inclusion in the Australian Register of Therapeutic Goods (ARTG) for use by healthcare professionals in a point-of-care setting. The COVID-19 & Flu Home Test is the first and only combined COVID-19 & Flu test to get emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for over-the-counter (OTC) use at home and other non-laboratory settings.

In March 2023, Cue Health, a healthcare technology company, announced the nationwide availability of a new line of consumer-friendly at-home diagnostic test kits. These simple kits give patients access to precise, reliable testing from the comfort of their own homes, allowing them to better manage their health. The tests have been integrated into Cue Care, the company's breakthrough test-to-treat service.

In July 2022, MedAccess, a social enterprise dedicated to promoting health in low- and middle-income countries, the Clinton Health Access Initiative (CHAI), and Wondfo, a biotechnology company, announced an agreement to make Wondfo's HIV self-test available for US$ 1. The price is more than 30% lower than the current lowest-priced World Health Organization (WHO) prequalified test and 50% less than the most extensively utilized test. This makes Wondfo's HIV self-test the least expensive WHO prequalified self-test on the market.